Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Acupuncture for Depression: Sigma-1 Receptor-Related Brain Network Modulation

12 november 2026 bijgewerkt door: Xinjing Yang, Shenzhen Hospital of Guangzhou University of Chinese Medicine

A Study on the Effects of Acupuncture in Treating Depression: Sigma-1 Receptor-Targeted pBFS for Individualized Brain Network Regulation and Prediction of Treatment Outcomes

This study will compare two types of acupuncture for adults with mild to moderate depression. One group will receive acupuncture. The other group will receive pivot acupuncture, a technique that uses needles at points on the head and neck. Participants with depression will be assigned to one of the two groups by chance. Both groups will attend three sessions a week for six weeks.

The researchers will compare how many people in each group have a substantial improvement in their depression symptoms by the end of treatment. They will also use brain scans and blood tests to examine whether symptom improvement is related to changes in how different parts of the brain work together and to changes in blood levels of a protein called the sigma-1 receptor.

Studie Overzicht

Toestand

Nog niet aan het werven

Gedetailleerde beschrijving

In this parallel-group randomized trial, 72 adults with a mild to moderate depressive episode will be assigned in a 1:1 ratio to acupuncture or pivot acupuncture. The allocation sequence will be generated using SAS and concealed in sequentially numbered, opaque, sealed envelopes until treatment assignment.

Structural brain MRI, resting-state functional MRI, and peripheral blood sampling will be performed at baseline and at the end of the six-week treatment period. The personalized brain functional sectors (pBFS) method will be used to define 92 functional brain regions for each participant and estimate pairwise functional connectivity. The investigators will examine associations among changes in connectivity, peripheral sigma-1 receptor levels, and depressive symptoms. They will also explore whether changes in connectivity can estimate the magnitude of symptom improvement and compare models based on individualized and group-level brain maps.

Studietype

Ingrijpend

Inschrijving (Geschat)

72

Fase

  • Niet toepasbaar

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studiecontact

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

18 jaar tot 60 jaar (Volwassen)

Accepteert gezonde vrijwilligers

Ja

Geslachten die in aanmerking komen voor studie

Allemaal

Beschrijving

Inclusion Criteria:

  • Aged 18 to 60 years, inclusive.
  • Right-handed.
  • Diagnosed with a depressive episode according to ICD-10 code F32 and meeting DSM-5 criteria for a depressive episode.
  • Mild to moderate depressive symptoms, defined as a baseline score of at least 8 and less than 24 on the 17-item Hamilton Depression Rating Scale (HAMD-17).
  • No use of immunomodulators, antidepressants, or other medications that affect mood in the month before enrollment.
  • Willing and able to follow study procedures and provide written informed consent.

Exclusion Criteria:

  • Another psychiatric disorder, such as bipolar disorder or schizophrenia.
  • Autoimmune disease or acute infection.
  • Intellectual disability (IQ below 70) or autism spectrum disorder.
  • History of epilepsy or a brain lesion.
  • History of drug dependence.
  • A contraindication to acupuncture, electroacupuncture, or MRI, such as an infectious condition that precludes needling, a history of fainting with needling, claustrophobia, or an MRI-incompatible intracranial implant.
  • Suicide risk identified at screening.
  • Current participation in another clinical trial.

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Behandeling
  • Toewijzing: Gerandomiseerd
  • Interventioneel model: Parallelle opdracht
  • Masker: Dubbele

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Experimenteel: Acupuncture

Participants will receive acupuncture three times a week for six weeks, for a total of 18 sessions. Each session will last 30 minutes.

The primary points are Baihui (GV20) and Yintang. Baihui is needled transversely from anterior to posterior to a depth of 0.5-0.8 cun. Yintang is needled slowly in a superior direction to a depth of 0.5-0.8 cun and gently rotated to de qi. Additional points are Shenmen (HT7), Neiguan (PC6), Sanyinjiao (SP6), Zusanli (ST36), and Taichong (LR3). Sterile acupuncture needles measuring 0.30 × 25 mm or 0.30 × 40 mm are used. Qualified practitioners with at least five years of clinical experience administer treatment.

Actieve vergelijker: Pivot Acupuncture

Participants will receive pivot acupuncture three times a week for six weeks, for a total of 18 sessions. Needles will be retained for 20 minutes at each session.

Needles are placed at Fengfu (GV16), Naohu (GV17), and bilateral Fengchi (GB20), Tianzhu (BL10), Wangu (GB12), Yifeng (TE17), Tianyou (TE16), and Anmian. With participants supine, the skin is disinfected with 75% alcohol. Sterile, single-use Huanqiu needles (Suzhou Huanqiu Acupuncture Medical Appliance Co., Ltd., China), 0.30 × 25 mm or 0.30 × 40 mm, are inserted rapidly. Fengchi is needled obliquely toward the tip of the nose to a depth of 10-23 mm. Fengfu is needled straight toward the mandible to a depth of 10-23 mm. Naohu is needled obliquely downward to a depth of 23 mm. Tianzhu, Wangu, Yifeng, Tianyou, and Anmian are needled perpendicularly to a depth of 30 mm. Needles are manipulated by lifting, thrusting, and rotating, then retained for 20 minutes. Treatment is administered without electrical stimulation.

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Percentage of Participants With a Clinical Response on the HAMD-17
Tijdsspanne: Baseline and Week 6 (end of treatment).

Clinical response is defined as a reduction of at least 50% from baseline in the total score on the 17-item Hamilton Depression Rating Scale (HAMD-17). The HAMD-17 is a clinician-rated measure of depressive symptom severity. Total scores range from 0 to 52, with higher scores indicating more severe symptoms.

Baseline and Week 6 (end of treatment).

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Percentage of Participants in Remission on the HAMD-17
Tijdsspanne: Week 6 (end of treatment).

Remission is defined as a total score below 8 on the 17-item Hamilton Depression Rating Scale (HAMD-17).

Week 6 (end of treatment).
Change From Baseline in HAMD-17 Total Score
Tijdsspanne: Baseline and Week 6 (end of treatment).

The Week 6 total score minus the baseline total score on the 17-item Hamilton Depression Rating Scale. Total scores range from 0 to 52, with higher scores indicating more severe symptoms. A negative change indicates improvement.

Baseline and Week 6 (end of treatment).
Change From Baseline in SF-12 Summary Score
Tijdsspanne: Baseline and Week 6 (end of treatment).

The 12-Item Short Form Health Survey (SF-12) is a self-reported measure of health status. Higher scores indicate better physical health. Change is calculated as the Week 6 score minus the baseline score.

Baseline and Week 6 (end of treatment).
Change From Baseline in BC-CCI-E Cognitive Complaints Score
Tijdsspanne: Baseline and Week 6 (end of treatment).

The British Columbia Cognitive Complaints Inventory-Expanded (BC-CCI-E) is a self-report measure of perceived cognitive difficulties. Higher cognitive complaints scores indicate more severe difficulties. Change is calculated as the Week 6 score minus the baseline score.

Baseline and Week 6 (end of treatment).
Suicide risk monitoring
Tijdsspanne: From enrollment through Week 10

Suicide risk will be assessed at baseline and weekly during the six-week treatment period using the Columbia-Suicide Severity Rating Scale (C-SSRS).

From enrollment through Week 10

Andere uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Percentage of Participants With at Least One Adverse Event
Tijdsspanne: From enrollment through Week 10

Adverse events will be recorded from enrollment through the final follow-up visit. The number and percentage of randomized participants with at least one adverse event will be summarized by treatment group.

From enrollment through Week 10

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Geschat)

1 december 2026

Primaire voltooiing (Geschat)

1 december 2027

Studie voltooiing (Geschat)

1 januari 2028

Studieregistratiedata

Eerst ingediend

12 november 2026

Eerst ingediend dat voldeed aan de QC-criteria

12 november 2026

Eerst geplaatst (Werkelijk)

18 november 2026

Updates van studierecords

Laatste update geplaatst (Werkelijk)

18 november 2026

Laatste update ingediend die voldeed aan QC-criteria

12 november 2026

Laatst geverifieerd

1 november 2026

Meer informatie

Termen gerelateerd aan deze studie

Andere studie-ID-nummers

  • NO.JCYJ20250604191311016

Plan Individuele Deelnemersgegevens (IPD)

Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?

ONBESLIST

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Nee

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren